Protocol Ledger

NCT06081920 · Phase II · RECRUITING

A Study of IBI363 in Subjects With Advanced Melanoma

Interventional Phase II clinical trial protocol NCT06081920 sponsored by Innovent Biologics (Suzhou) Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-19 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06081920
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06081920
Protocol FieldVerified Registry Value
NCT IdentifierNCT06081920
Consolidated Lead SponsorInnovent Biologics (Suzhou) Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2023-10-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06081920
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
Nanjing Drum Tower HospitalNanjing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI